- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05936567
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
April 9, 2024 updated by: Incyte Corporation
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
136
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Incyte Corporation Call Center (US)
- Phone Number: 1.855.463.3463
- Email: medinfo@incyte.com
Study Contact Backup
- Name: Incyte Corporation Call Center (ex-US)
- Phone Number: +800 00027423
- Email: eumedinfo@incyte.com
Study Locations
-
-
-
Berlin, Germany, 12200
- Not yet recruiting
- Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
-
Dresden, Germany, 01307
- Recruiting
- Universitaetsklinikum Carl Gustav Carus TU Dresden
-
Frankfurt, Germany, 60590
- Recruiting
- Universitatsklinikum Frankfurt
-
Hamburg, Germany, 22391
- Recruiting
- MENSINGDERMA research GmbH
-
Kiel, Germany, 24105
- Recruiting
- Universitaetsklinikum Schleswig-Holstein - Campus Kiel
-
Leipzig, Germany, 04103
- Recruiting
- Universitätsklinikum Leipzig AöR
-
Mainz, Germany, 55131
- Recruiting
- Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
-
Osnabrück, Germany, 49074
- Recruiting
- Klifos - Klinische Forschung Osnabruck
-
Tuebingen, Germany, 72076
- Recruiting
- Universitats-Hautklink Tubingen
-
-
-
-
-
Bialystok, Poland, 15-375
- Recruiting
- Specderm Poznanska
-
Katowice, Poland, 40-081
- Recruiting
- Centrum Medyczne Pratia Katowice I
-
Lublin, Poland, 20-552
- Recruiting
- Centrum Alergologii Sp Z.O.O
-
Opole, Poland, 45-401
- Not yet recruiting
- University Clinical Hospital
-
Poznan, Poland, 60-529
- Recruiting
- Solumed Centrum Medyczne
-
Poznan, Poland, 60-693
- Recruiting
- Specjalistyczny Nzoz Alergologia Plus
-
Swidnica, Poland, 58-100
- Recruiting
- Dc-Med
-
Warszawa, Poland, 02-793
- Recruiting
- Etg Warszawa
-
Warszawa, Poland, 02-507
- Not yet recruiting
- Centralny Szpital Kliniczny Mswia
-
Warszawa, Poland, 02-953
- Recruiting
- Klinika Ambroziak
-
Wroclaw, Poland, 50-449
- Recruiting
- Melita Medical Sp. Z O. O.
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Recruiting
- Clinical Research Center of Alabama
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Recruiting
- Foothills Research Center
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- Little Rock Allergy Asthma, Pa Clinical Research Center Lraac
-
North Little Rock, Arkansas, United States, 72117
- Recruiting
- Arkansas Research Trials
-
-
California
-
Fountain Valley, California, United States, 92708
- Recruiting
- First OC Dermatology
-
Newport Beach, California, United States, 92663
- Recruiting
- Newport Native Md
-
Palmdale, California, United States, 93551
- Recruiting
- Antelope Valley Allergy Medical Group
-
Redwood City, California, United States, 94063
- Recruiting
- Allergy and Asthma Consultants, Pc
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Recruiting
- Treasure Valley Medical Research
-
-
Illinois
-
Normal, Illinois, United States, 61761
- Recruiting
- Midwest Allergy Sinus Asthma, SC
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48103
- Recruiting
- David Fivenson, MD, Dermatology, PLLC
-
Troy, Michigan, United States, 48084
- Recruiting
- Revival Research Institute, Llc Troy
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Recruiting
- The Clinical Research Center Crc, Llc
-
-
Ohio
-
Columbus, Ohio, United States, 43235
- Recruiting
- Optimed Research Ltd
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74136
- Recruiting
- Vital Prospects Clinical Research Institute, Pc Vpcri
-
-
Pennsylvania
-
Sugarloaf, Pennsylvania, United States, 18249
- Recruiting
- Dermdox Center For Dermatology
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- Recruiting
- Allergy and Asthma Center of Charleston
-
-
Texas
-
San Antonio, Texas, United States, 78212
- Recruiting
- Rainey and Finklea Dermatology
-
-
Washington
-
Bellingham, Washington, United States, 98225
- Recruiting
- Bellingham Asthma, Allergy Immunology Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
- CSU diagnosis for ≥ 3 months prior to screening.
- CSU refractory to second-generation H1 antihistamines
- Participants must have been on a stable dose of second-generation H1 antihistamine, and must agree to maintain the stable dose of second-generation H1 antihistamine throughout study.
- Willingness and ability to comply with the study Protocol and procedures.
- Further inclusion criteria apply
Exclusion Criteria:
- Treatment with an anti-IgE biologic (eg, omalizumab) within 8 weeks prior to screening.
- Clearly defined underlying etiology for chronic urticarias other than CSU
- Other cutaneous or systemic diseases with chronic itching or with symptoms of urticaria or angioedema.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Concurrent or history of Thrombocytopenia, coagulopathy, or platelet dysfunction, Venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure (NYHA Class III or IV), cerebrovascular accident, MI, coronary stenting, or CABG surgery, other significant cardiovascular diseases or uncontrolled hypertension
- Recipient of an organ transplant that requires continued immunosuppression.
- Any malignancies or history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ.
- Chronic or recurrent infectious disease.
- Further exclusion criteria apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Povorcitinib Dose A
Participants will receive dose A of povorcitinib for a 12 week period, followed by dose A for an additional 24 week period.
|
oral; tablet
|
Experimental: Povorcitinib Dose B
Participants will receive dose B of povorcitinib for a 12 week period, followed by dose B for an additional 24 week period.
|
oral; tablet
|
Experimental: Povorcitinib Dose C
Participants will receive dose C of povorcitinib for a 12 week period, followed by dose C for an additional 24 week period.
|
oral; tablet
|
Experimental: Placebo followed by Povorcitinib Dose A, B, or C
Participants will receive placebo for a 12 week period, followed by randomization to either Dose A, Dose B, or Dose C for an additional 24 week period.
|
oral; tablet
oral; tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the urticaria activity score (UAS7)
Time Frame: 12 Weeks
|
Defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS, at week 12. UAS scores range from 0-42; with higher scores reflecting greater disease activity.
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants who achieve UAS7 ≤ 6 (controlled disease) at Week 12
Time Frame: 12 Weeks
|
Defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS, at week 12. UAS scores range from 0-42; with higher scores reflecting greater disease activity.
|
12 Weeks
|
Time to first achievement of UAS7 ≤ 6 (controlled disease) during the PC period
Time Frame: 12 Weeks
|
Defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS.
UAS scores range from 0-42; with higher scores reflecting greater disease activity.
|
12 Weeks
|
Proportion of participants with UAS7 = 0 at Week 12.
Time Frame: 12 Weeks
|
Defined as the 7-day sum of the individual, daily recorded scores for HSS and ISS, at week 12. UAS scores range from 0-42; with higher scores reflecting greater disease activity.
|
12 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 31, 2023
Primary Completion (Estimated)
March 7, 2025
Study Completion (Estimated)
September 5, 2025
Study Registration Dates
First Submitted
June 26, 2023
First Submitted That Met QC Criteria
July 6, 2023
First Posted (Actual)
July 7, 2023
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INCB54707-207
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Angioedema
-
Pharvaris Netherlands B.V.Active, not recruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
-
Pharvaris Netherlands B.V.CompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsBulgaria, United States, Spain, Israel, Germany, Canada, Czechia, France, Hungary, Italy, Netherlands, Poland, United Kingdom
-
Pharvaris Netherlands B.V.RecruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States
-
Pharvaris Netherlands B.V.RecruitingHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditionsUnited States, Bulgaria, Czechia, Hungary, Spain, France, Germany, Poland, Canada, Israel
-
CENTOGENE GmbH RostockCompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | C1 Esterase Inhibitor Deficiency | HAE | Angio Edema | C4 Deficiency | Hereditary Angioedema Type IIITurkey, Armenia, Georgia, India, Peru, Poland, Romania
-
University of Wisconsin, MadisonNovartis PharmaceuticalsCompletedIdiopathic AngioedemaUnited States
-
ShireTerminatedACE Inhibitor Induced AngioedemaUnited States
-
Vanderbilt University Medical CenterShireTerminatedACE Inhibitor-associated AngioedemaUnited States
-
HAE Global Registry FoundationRecruitingHereditary Angioedema Type I and IIItaly
Clinical Trials on Povorcitinib
-
Incyte CorporationCompletedHidradenitis SuppurativaUnited States
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Canada, Czechia, Spain, Germany, Poland, Netherlands, Belgium, France, Greece, Japan, Austria
-
Incyte CorporationActive, not recruitingPrurigo NodularisUnited States, Canada, Germany, Poland, Puerto Rico, Spain
-
Incyte CorporationCompletedHidradenitis Suppurativa | Acne InversaUnited States, Canada, France, Germany, Poland, Spain
-
Incyte CorporationRecruitingHidradenitis Suppurativa (HS)United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
-
Incyte CorporationCompletedKidney Diseases | Renal InsufficiencyUnited States, Germany
-
Incyte CorporationCompletedKidney Diseases | Renal InsufficiencyUnited States, Germany
-
Incyte CorporationRecruitingKidney Diseases | Renal InsufficiencyUnited States, Germany
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada